Opendata, web and dolomites

BIOCOPY SIGNED

BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIOCOPY project word cloud

Explore the words cloud of the BIOCOPY project. It provides you a very rough idea of what is the project "BIOCOPY" about.

coated    services    analogous    dna    spin    upfront    free    discovery    describing    covers    world    60    coatings    payments    tailor    responsible    clinical    projected    antibodies    billion    obtaining    therapeutics    protein    biology    manufacturing    mixes    transfer    biotechnology    assay    biocopy    diagnostics    bioactive    acute    template    academic    companies    recovered    microsystems    cheaper    2019    annum    vaccines    technological    university    market    molecules    physics    line    11    approval    freiburg    plan    made    5m    expertise    team    biomolecules    100    drug    first    feasibility    either    awarded    completely    off    2025    engineering    screenings    days    revenues    candidates    generation    dollar    patented    output    copied    opens    borned    dimensions    pharmaceuticals    biosensors    molecular    photocopier    business    vaccine    technique    milestone    surface    character    supplying    disruptive    biotech    copy    rna    royalty    catalysts    commercialization    binding    innovative    enzymes    label    pharma    company    biochemical   

Project "BIOCOPY" data sheet

The following table provides information about the project.

Coordinator
BIOCOPY GMBH 

Organization address
address: SPECHTWEG 25
city: FREIBURG IM BREISGAU
postcode: 79110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.biocopy.de/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOCOPY GMBH DE (FREIBURG IM BREISGAU) coordinator 50˙000.00

Map

 Project objective

'BioCopy is a spin-off company borned in the University of Freiburg. We have developed an innovative, patented technique to copy biomolecules analogous to a photocopier. A DNA-coated surface is used as copy template. By supplying different biochemical 'copy mixes', either a DNA, a RNA or a protein copy is generated. After the copy process, the copied biomolecules can be analyzed label-free for their specific binding to target molecules and recovered as potential candidates for a future use as therapeutics or diagnostics. The BioCopy technology completely opens up new dimensions for drug development, vaccines, antibodies, enzymes, catalysts, bioactive coatings, and biosensors and it has are more than 40 future applications. We plan to offer 3 products and services to pharma and biotech companies, related with high- output and cheaper molecular biology screenings. The most promising line is the tailor-made discovery of vaccine candidates within two days. This will have a disruptive character, because the first generation of a vaccine is a billion-dollar market, projected to rise $60 billion on 2019, with 11% growth per annum, and to $100 billion by 2025. BioCopy will provide vaccine candidates to pharmaceuticals, obtaining revenues through upfront, milestone and royalty payments, and they will be responsible for the vaccine´s clinical development, approval and distribution. The multi-awarded BioCopy team covers business know-how and expertise in biology, physics, manufacturing systems engineering, assay development and microsystems technology. BioCopy aims to contribute to the European challenges related with advanced biotechnology applications in pharma sector, and to increase the technological transfer from the academic world into the manufacturing sector. During phase 1 we will build up a detailed business plan and a feasibility study, describing all the needed activities in order to reach BioCopy commercialization. We will need about €2.5M in phase 2.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOCOPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOCOPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More